Merck & Co., Inc. (NYSE:MRK) has explored a potential acquisition of Swiss biotech firm MoonLake Immunotherapeutics in a deal ...

Merck has held talks to buy Swiss biotech MoonLake Immunotherapeutics for more than $3 billion, the Financial Times reported ...

After a back and forth with two potential buyers, bluebird bio has completed its sale to funds managed by global investment ...

Discover how Bayer and BlueRock are redefining biotech partnerships. From breakthrough Parkinson’s therapies to a unique “arm ...